Vespa Capital completed the investment in FibroFind.

Vespa Capital, a private equity firm, completed the investment in FibroFind, a pre-clinical contract research organisation. Financial terms were not disclosed. "Partnering with Vespa Capital marks an exciting step in FibroFind’s growth journey. We are already seeing strong international demand for our platform, and this investment will allow us to scale further, broaden our reach across therapeutic areas, and deepen our impact in pre-clinical drug development. As regulatory and industry momentum continues to shift towards human-relevant models, we are ideally placed to help our clients make faster, more confident decisions with better data," Jelena Mann, FibroFind CEO.